GT Biopharma, Inc.
GTBPNasdaq
$0.36
↓ -7.2%Jul 17 close · end-of-day
Price
1Y↓ -82.6%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$10.8M
Enterprise Value
$1.9M
P/E
—
P/S
—
P/B
1.4
EV/EBITDA
—
PEG
—
FCF Yield
—
Dividend Yield
—
Revenue (TTM)
—
Net Income (TTM)
-$30.4M
Free Cash Flow (TTM)
—
Gross Margin
—
Operating Margin
—
Net Margin
—
ROE
-401.2%
ROIC
—
Debt / Equity
—
Net Cash
$8.9M
Return 1Y
-82.5%
Company profile
GT Biopharma, Inc. focuses on the development and commercialization of immuno-oncology products based on its proprietary Tri-specific Killer Engager (TriKE) fusion protein immune cell engager technology platform. GTB-3550, a single-chain tri-specific recombinant fusion protein conjugate, is in Phase I/II clinical trial for the treatment of myelodysplastic syndromes, refractory/relapsed acute myeloid leukemia or advanced systemic mastocytosis, and CD33+ malignancies. The company was formerly known as OXIS International, Inc
- CEO
- Michael Breen
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 8
- Headquarters
- California
- Website
- gtbiopharma.com
Earnings
GTBP Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue——
Diluted EPS-$0.11↓ -66.7%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $0.00 | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$6.8M | -$57.5M | -$21.3M | -$13.6M | -$14.4M | -$12.4M |
| Net income | -$28.3M | -$58.0M | -$20.9M | -$7.6M | -$13.2M | -$28.4M |
| Diluted EPS | — | — | -$19.66 | -$5.64 | -$6.94 | -$6.68 |
| Operating cash flow | -$7.3M | -$15.6M | -$15.2M | -$8.9M | -$12.9M | -$12.9M |
| Free cash flow | — | — | — | — | — | — |
| Gross margin | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — |
| Net margin | — | — | — | — | — | — |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$3.9M | -$3.6M | -$3.8M | -$1.9M | -$1.5M | -$3.4M | -$5.6M | -$2.8M |
| Net income | -$3.7M | -$3.4M | -$3.8M | -$776,000.00 | -$30.2M | $8.3M | -$5.7M | -$2.8M |
| Diluted EPS | -$2.17 | -$1.53 | -$1.60 | -$0.33 | -$10.92 | $1.04 | $3.53 | -$0.11 |
| Operating cash flow | -$3.5M | -$2.7M | -$2.5M | -$2.2M | -$3.0M | -$3.7M | -$4.0M | -$2.5M |
| Free cash flow | — | — | — | — | — | — | — | — |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — | — | — |
| Net margin | — | — | — | — | — | — | — | — |
Company news
Jun 1, 2026
May 14, 2026
Apr 20, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
No insider transactions in the last 12 months.
No insider transactions on file.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.